Search clinical trials for: Noristerat(BAY86-6308)

Total 571 results

Bayer

Completed

Clinical Study Investigating the Conversion of the Contraceptive Compound Norethisterone Within the Body Towards the Contraceptive Compound Ethinylestradiol

Pharmacokinetics

Germany
FORUM Pharmaceuticals Inc

Completed

Study of EVP-6308 to Assess the Dose- and Concentration-dependent Displacement of [18F]MNI-659 by EVP-6308

Healthy

United States
Bayer

Completed

Gadobutrol Magnevist-controlled Body Study

Magnetic Resonance Imaging

China, Korea, Republic of, Japan
Bayer

Completed

Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Vascular Diseases in Chinese Patients

Vascular Diseases

China
Life Molecular Imaging SA

Completed

PET/CT (Positron Emission Tomography / Computed Tomography) Investigations With BAY86-9596 (18F) (300 MBq) Following Single Intravenous Administration in Patients With Cancer or Inflammations.

Diagnostic Imaging

Singapore
Bayer

Completed

A Study, Called UV Population, to Learn More About the Safety of the Study Drug Ultravist, Which is Given to Get Clearer X-ray Pictures, in People of Different Sexes, Races, and From Different Countries/Regions

Contrast Enhanced X-ray Based Examination

Germany
Bayer

Completed

Japanese BAY86-9766 Monotherapy Phase I Study

Neoplasms

Japan
Chong Kun Dang Pharmaceutical

Completed

Clinical Trial to Evaluate the Drug Drug Interaction of CKD-501 and D308

Diabetes Mellitus, Type II

Korea, Republic of
FORUM Pharmaceuticals Inc

Completed

Study to Assess the Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Effects of EVP-6308 and the Potential of EVP-6308 to Affect the PK Properties of the Antipsychotic Regimen in Subjects With Schizophrenia Currently Receiving Stable Treatment With up to 2 Atypical Antipsychotics

Schizophrenia

United States
Bayer
Titan Pharmaceuticals

Terminated

Pilot Study of Safety and Efficacy of Spheramine

Parkinson''s Disease

United States
Bayer

Completed

Safety of Gadovist in Renally Impaired Patients (GRIP)

Fibrosis | Renal Impairment

Italy, Spain, Korea, Republic of, Germany, Canada, France, Austria, Thailand, Australia, Switzerland
Bayer
Titan Pharmaceuticals

Terminated

STEPS Trial - Spheramine Safety and Efficacy Study

Parkinson Disease

Spain, United States, Germany
Bayer
TAP Pharmaceutical Products Inc.

Completed

Menorrhagia Study in Women With Treatment-resistant Menorrhagia

Menorrhagia
Bayer

Completed

Safety and Efficacy of Gadobutrol 1.0 Molar in Japanese Subjects for CNS Imaging

Magnetic Resonance Imaging

Japan
Bayer

Completed

Observational Study on the Safety and Tolerability of Gadobutrol (Gadovist) Among Filipino Patients in Magnetic Resonance Imaging

Magnetic Resonance Imaging

Philippines
Bayer

Completed

A Study to Learn More About the Safety of Ultravist in Children and in the Elderly

Hypersensitivity

Germany
Bayer

Completed

Gadobutrol Pharmacokinetic and Safety Study in Pediatric Subjects Aged <2 Years (Term Newborn Infants to Toddlers 23 Months of Age Inclusive)

Magnetic Resonance Imaging

United States, Canada, Germany
Bayer

Completed

Gadobutrol Enhanced MRA of the Renal Arteries (GRAMS)

Renal Artery Obstruction

Taiwan, United States, Korea, Republic of, France, Turkey, Switzerland, Austria, Poland, Brazil, Colombia, Germany, Czech Republic, Argentina
Bayer

Completed

PMS Study Ultravist-IMAGE, IoproMide (UltrAvist) to Gain Further Information on Tolerability and Safety in X-ray Examination (IMAGE)

Diagnostic Imaging

Poland, China, Germany, Hungary, Indonesia, Korea, Republic of, Malaysia, Saudi Arabia, Singapore, Thailand, Philippines, Taiwan, Italy, Moldova, Republic of, Romania, Russian Federation, Ukraine, Bosnia and Herzegovina, Pak... and more
Repare Therapeutics
Debiopharm International SA

Recruiting

Study of RP-6306 Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors (MYTHIC)

Advanced Solid Tumor

United States, Canada, Denmark
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Not yet recruiting

An Phase III Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With PsO

Plaque Psoriasis Patients
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Not yet recruiting

A Study to Evaluate 608 in Patients With Ankylosing Spondylitis (AS)

Ankylosing Spondylitis

China
Bayer

Completed

Gadobutrol Enhanced MRA of the Supra-aortic Vessels (GEMSAV)

Carotid Stenosis

France, China, United States, Austria, Poland, Australia, Italy, Turkey, Germany, Korea, Republic of, Sweden, Switzerland, Czechia, Argentina
Bayer

Completed

GARDIAN, Gadovist in Routine Diagnostic Magnetic Resonance Imaging Administration in Non-selected Patients (GARDIAN)

Magnetic Resonance Imaging | Magnetic Resonance Angiography

Poland, China, France, Germany, Hungary, Korea, Republic of, South Africa, Spain, Thailand, Taiwan, Czech Republic, Hong Kong, Italy, Kazakhstan, Russian Federation, Bosnia and Herzegovina, Greece, Canada, Vietnam, Kyrgyzstan
Bayer

Completed

Patient Characteristics in Daily Radiological Practice of Gadovist® Application (PATRON)

Epidemiologic Factors

Germany
Bayer

Completed

Qlaira rPMS (Regulatory Post Marketing Surveillance) Study in Korea

Contraception

Korea, Republic of
Bayer

Completed

Julina Post-marketing Surveillance for Climacteric Symptoms in Japan (JULINA-CLIMA)

Osteoporosis, Postmenopausal

Japan
Bayer

Completed

Julina Post-marketing Surveillance for Postmenopausal Osteoporosis in Japan

Osteoporosis, Postmenopausal

Japan
Bayer

Completed

Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate Renal Insufficiency After the Administration of Magnevist

Fibrosis | Renal Insufficiency | Kidney Failure

United States
Bayer

Completed

Myocardial Perfusion MRI

Magnetic Resonance Imaging | Myocardial Perfusion Imaging

Switzerland, Germany, Austria, Poland
Bayer

Completed

Safety and Efficacy of Gadobutrol 1.0 Molar ( Gadavist ) in Patients for Central Nervous System (CNS) Imaging

Central Nervous System Diseases

Korea, Republic of, United States, Colombia, China, Argentina
Bayer

Completed

Comparison Study of Vasovist® Magnetic Resonance Angiography (MRA) and an MRA With a Conventional Extracellular Contrast Agent With X-ray Angiography in Patients With Peripheral Artery Disease

Peripheral Vascular Diseases

Germany, Switzerland, Argentina, Austria, Mexico, Brazil
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Not yet recruiting

A Study to Evaluate 608 in Patients With Non- Radiographic Axial Spondyloarthritis (Nr-axSpA)

Axial Spondyloarthritis

China
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating IMA-638 in Asthma

Asthma

United States
Bayer

Completed

A Study Called GUS to Understand How Much of the Contrast Agent Gadavist is Used and How Much is Wasted in Two Different Containers (Single-dose Vials and Imaging Bulk Packages ) in a Real-world Setting

Contrast Enhancement in Magnetic Resonance Imaging

United States
Bayer

Completed

Drug Use Investigation of Gadovist.

Magnetic Resonance Imaging | Image Enhancement

Japan
Bayer

Completed

Depiction of Delayed Enhancement in Patients With Documented Myocardial Infarction

Myocardial Infarction

United States, Argentina
Bayer

Completed

Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI) (GEMMA 2)

Breast Cancer

Spain, Canada, Taiwan, United States, India, Netherlands, Poland, Germany, Argentina
Bayer

Completed

Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast MRI

Breast Cancer | Diagnostic Imaging

Italy, Korea, Republic of, Switzerland, Colombia, United States, Brazil, Germany, Finland, Argentina
Bayer

Completed

Safety and Efficacy of SH T00660AA in Treatment of Endometriosis

Endometriosis

Italy, Germany, Ukraine
Repare Therapeutics

Active, not recruiting

Study of RP-6306 With FOLFIRI in Advanced Solid Tumors (MINOTAUR)

Advanced Solid Tumor

United States, Canada, Spain, United Kingdom
Janssen Research & Development, LLC

Completed

A Single Ascending Dose Study in Healthy Participants and Multiple Dose Study of JNJ-55920839 in Participants With Mild to Moderate Systemic Lupus Erythematosus

Healthy | Systemic Lupus Erythematosus

United States, Spain, Romania, Taiwan, Belgium, Poland, Moldova, Republic of
Bayer
Navitas Life Sciences GmbH; LKF Laboratory

Completed

Efficacy of Gynodian® Depot in Women With Impaired Well-being

Hormone Replacement Therapy
Boehringer Ingelheim

Completed

Relative Bioavailability and Tolerability of Various Experimental Formulations of BIBV 308 SE in Healthy Subjects

Healthy
Bayer

Completed

Gadobutrol / Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD) (GadaCAD 2)

Coronary Artery Disease

United States, Canada, Singapore, Australia
Bayer

Completed

Gadobutrol/Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD) (GadaCAD 1)

Coronary Artery Disease

New Zealand, United Kingdom, United States, France, Germany, Korea, Republic of, Switzerland
Bayer

Completed

Contrast-enhanced MRI in Children 2 Months to <2 Years

Magnetic Resonance Imaging

United States, Germany
Bayer

Completed

A Study of Magnetic Resonance Imaging (MRI) With Gadavist in Children

Magnetic Resonance Imaging

Sweden, Canada, Austria, Germany
Bayer

Completed

Magnevist® Injection Enhanced MRA at Two Dose Levels Compared to Non Contrast MRA for the Detection of Structural Abnormalities of the Infrarenal Aorta and Peripheral Arteries

Peripheral Vascular Disease
Bayer

Completed

Magnevist Post-marketing Surveillance in Japan

Diagnostic Imaging

Japan

3

Subscribe